All In Biotech

Drug Trial Radar · NCT03510325

Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)

Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments

Last checked: Nov 19, 2026Latest source record: Apr 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 762 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

762

Actual

Start

Feb 12, 2019

Primary completion

Sep 27, 2023

Study completion Sep 27, 2023

Sponsor

Lead sponsor
Shanghai Mental Health CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 27, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Sequential
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 16 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a sequential multiple-assignment randomized trial (RCT) of antipsychotic medication treatment in first-episode schizophrenia patients in the real-world settings.Through analysis of treatment efficacy rate and adverse reactions and pharmacoeconomic evaluation, this project intends to provide evidence for the selection of antipsychotics in FES patients as well as the efficacy and safety of using clozapine in the early phase of schizophrenia treatment by comparing with other SGAs.

Conditions

  • Schizophrenia

Interventions

  • Phase 1: OlanzapineDrug

    Initial dosage: 5-10 mg; recommended dosage: 5-20 mg/d; dosage form: po. duration: 8 weeks

  • Phase 1: RisperidoneDrug

    Initial dosage: 1-2 mg; recommended dosage: 2-6 mg/d; dosage form: po. duration: 8 weeks

  • Phase 1: AmisulprideDrug

    Initial dosage: 200-400 mg; recommended dosage: 400-1200 mg/d; dosage form: po. duration: 8 weeks

  • Phase 1: AripiprazoleDrug

    Initial dosage: 5-10 mg; recommended dosage: 10-30 mg/d; dosage form: po. duration: 8 weeks

  • Phase 1: PerphenazineDrug

    Initial dosage: 2-4 mg; recommended dosage: 6-36 mg/d; dosage form: po. duration: 8 weeks

  • Phase 2: OlanzapineDrug

    Initial dosage: 5-10 mg; recommended dosage: 5-20 mg/d; dosage form: po. duration: 8 weeks

  • Phase 2: AmisulprideDrug

    Initial dosage: 200-400 mg; recommended dosage: 400-1200 mg/d; dosage form: po. duration: 8 weeks

  • Phase 2: ClozapineDrug

    Initial dosage: 25-50 mg; recommended dosage: 200-400 mg/d; dosage form: po. duration: 8 weeks

  • Phase 3A: Clozapine extended treatment or Combined clozapine-MECT therapyOther

    Clozapine extended treatment: dosage: 200-600 mg/d; dosage form: po. Combined clozapine-MECT therapy: Dosage of clozapine: 200-600 mg/d; The modified electroconvulsive therapy (MECT) will be administered three times per week for the first 2 weeks, then twice a week for the next 2 weeks. The total treatment duration is about one month.

  • Phase 3B: Clozapine or another SGAsDrug

    Clozapine: Initial dosage: 25-50 mg; recommended dosage: 200-600 mg/d; duration: 8 weeks Another Second generation antipsychotics (SGAs) (not previously used in phase 1 and 2): Olanzapine, risperidone, amisulpride, or aripiprazole The dosage of each drug is the same as that of phase 1 and phase 2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment efficacy rateTime frame: baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months
  2. All-cause dropout rateTime frame: baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Anding Hospital of Capital Medical University

    Beijing, Beijing Municipality, China

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, China

  • Nanjing Brain Hospital Affiliated to Nanjing Medical University

    Nanjing, Jiangsu, China

  • Dalian Seventh People's Hospital

    Dalian, Liaoning, China

  • Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China

  • First Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, China

  • Hangzhou Seventh People's Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.